© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Imbruvica plus Gazyva is the first chemotherapy-free regimen for chronic lymphocytic leukemia.
Venclexta alone or in combination with Rituxan improved progression-free survival in patients with chronic lymphocytic leukemia.
Researchers believe their greater understanding of leukemia stem cells will lead to more treatment options for people with the blood cancer.
A look back at some of the major news stories we covered this year.
Tafinlar (dabrafeb) plus Mekinist (trametinib) shrank tumors in people with biliary tract cancer and adenocarcinoma of the small intestine.
Asparlas approved for children and young adults with acute lymphoblastic leukemia.
Elzonris approved for bone marrow disease that can evolve into leukemia.
Long-term remission seen in children with leukemia and adults with lymphoma.
Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.
Customized cell therapy plus Imbruvica leads to high response rate.
ASH 2018 conference highlights precision medicine, machine learning and gut microbiome.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
